SCHEMBL6808765

SCHEMBL6808765

Cc1c(C(F)(F)F)[nH]c2c(C(=O)Nc3cccc(-n4cncn4)c3)cccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.43
NR2E1 Q9Y466 4/20 0.41
S1PR1 P21453 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAP3K5 Q99683 1/20 0.39
GRM5 P41594 1/20 0.38
RXFP1 Q9HBX9 5/20 0.38
MALT1 Q9UDY8 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
LCK P06239 1/20 0.36
KIT P10721 1/20 0.36
SRC P12931 1/20 0.36
KDR P35968 1/20 0.36
MAPK14 Q16539 1/20 0.36
ROCK1 Q13464 1/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805289 0.81 MEN1 (0.42) SMN1; SMN2S1PR1MAP3K5GRM5NPC1
SCHEMBL6804288 0.79 LCK (0.45) GRM5RXFP1LCKKITSRC
SCHEMBL6804275 0.76 MAPK14 (0.48) RXFP1LCKKITSRCKDR
SCHEMBL6805348 0.74 DYRK1A (0.43) GRM5RXFP1KITKDR
SCHEMBL26098811 0.73 SETD2 (0.65) S1PR1RXFP1NPC1RAB9A
SCHEMBL4457861 0.72 S1PR1 (0.47) SMN1; SMN2S1PR1CYP1A2CYP3A4CYP2C9
SCHEMBL6803412 0.69 KMT2A (0.39) NR2E1MAP3K5GRM5NPC1RAB9A
SCHEMBL24683182 0.69 SCN10A (0.41)
SCHEMBL6755760 0.68 PBRM1 (0.47) SMN1; SMN2KDR
SCHEMBL6754407 0.66 HTR2C (0.64) CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266774-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed
US-6770667-B1 N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-03 US disclosed
EP-1216240-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-06-26 EP disclosed
WO-2001025229-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266774-A1 Amide compounds TPH1, HTR1A, HTR5A SMN1; SMN2 3815/4885NR2E1 1288/4885S1PR1 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.